Shares of IBM rocketed 10.2% in Monday pre-market trading to $328.03, capping an extraordinary stretch that has seen the stock climb roughly 31% from its May 22 close of $253.84. The catalyst: Barclays initiated coverage with an Overweight rating and a $350 price target, implying about 17.5% upside from the previous close. For shareholders, the question is whether IBM's sudden rebranding as an AI-and-quantum play can sustain a valuation that, just days ago, few on Wall Street envisioned.
Software Is Now IBM's Profit Engine, and That Changes the Math. Barclays analyst Raimo Lenschow noted that nearly half of IBM's revenue and most of its profit now come from software, a mix expected to grow as software outpaces other segments. That matters because software carries higher margins and more predictable recurring revenue than IBM's legacy consulting and hardware lines. The analyst expects mid-single-digit organic revenue growth alongside continued margin expansion — modest by Silicon Valley standards, but attractive for a company generating roughly $4.9 billion in quarterly free cash flow with a 2.6% dividend yield.
Government Money Supercharged the Rally Before Barclays Arrived. IBM unveiled a $15 billion strategic package: $10 billion over five years to scale quantum computing and $5 billion for an enterprise AI security initiative.
The U.S. Department of Commerce awarded IBM $1 billion under the CHIPS Act to establish a quantum chip foundry, and IBM pledged an additional $1 billion to create a new spinout that will build and operate the facility. For investors, this is Washington essentially co-funding IBM's next-generation bet, reducing the capital risk shareholders would otherwise bear alone.
Regulated Customers Are a Shield — Until They Aren't. Lenschow noted IBM's infrastructure software serves large, heavily regulated enterprises, creating a sticky customer base unlikely to face significant disruption from AI. That defensive positioning explains why Barclays sees steady earnings growth. But balance-sheet risk is real: IBM carries over $60 billion in long-term debt with a debt-to-equity ratio around 2.1x. If AI spending cools or interest costs bite, that leverage cuts both ways.
The Stock Has Already Outrun Most of Wall Street. At $328, IBM trades above Barclays' freshly minted $350 target by just 6.7%, and well beyond the prior consensus price target of roughly $274 based on 18 analysts.
Q1 earnings of $1.91 per share beat estimates by $0.10 on revenue of $15.92 billion, up 9.5% year-over-year — solid, not spectacular. Investors buying here are betting that IBM's quantum and AI narrative will pull the rest of the Street's targets sharply higher. If that narrative stalls, the stock has a long way to fall back to earth.